HIF-PHIs associated with embolic and thrombotic events: a real-world pharmacovigilance study based on the Japan Adverse Drug Event Report database
Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) play an important role in the treatment of renal anemia. However, some studies suggest a potential link between HIF-PHIs and increased thrombosis risk, though these findings are inconsistent and lack large-scale clinical su...
Saved in:
| Main Authors: | Danna Wu, Shuxin Jiao, Hongru Lin, Peitao Xie, Guohao Cai, Mingdao Lin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2025.2491655 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Issues on clinical application of hypoxia-inducible factor prolyl hydroxylase inhibitor Roxadustat
by: TU Yan, et al.
Published: (2020-01-01) -
Progress of HIF-1α and HIF-PHI in vascular calcification of chronic kidney disease
by: WANG Ao, et al.
Published: (2024-08-01) -
A Case Report of Hypothyrotropin Hypothyroidism Caused by Roxadustat
by: YAN Xuelian, et al.
Published: (2025-03-01) -
Prolyl Hydroxylase Inhibitor-Mediated HIF Activation Drives Transcriptional Reprogramming in Retinal Pigment Epithelium: Relevance to Chronic Kidney Disease
by: Tamás Gáll, et al.
Published: (2025-07-01) -
The role and clinical implications of HIF-PHI daprodustat in dialysis-dependent and non-dialysis-dependent chronic kidney disease anemic patients: a general review
by: Yousuf Abdulkarim Waheed, et al.
Published: (2024-12-01)